ABUS

Arbutus Biopharma Corp

Add to Watchlist

Advanced Chart

3.340

+0.12(3.727%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.400

Open

3.2577

VWAP

Vol

763.59K

Mkt Cap

616.72M

Low

3.245

Amount

EV/EBITDA(TTM)

Total Shares

188.72M

504.01M

EV/OCF(TTM)

P/S(TTM)

95.23

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

721.05K

-54.04%

1.58M

+18.68%

1.60M

-6.84%

Estimates Revision

The market is revising Downward the revenue expectations for Arbutus Biopharma Corporation (ABUS) for FY2025, with the revenue forecasts being adjusted by -13.73% over the past three months. During the same period, the stock price has changed by 0.00%.

Revenue Estimates for FY2025

Revise Downward

-13.73%

In Past 3 Month

Stock Price

No Change

0.00%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Arbutus Biopharma Corp (ABUS.O) is -16.34, compared to its 5-year average forward P/E of -6.63. For a more detailed relative valuation and DCF analysis to assess Arbutus Biopharma Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.63

Current PE

-16.34

Overvalued PE

-3.09

Undervalued PE

-10.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.11

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.36

Undervalued EV/EBITDA

-7.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

46.09

Current PS

116.57

Overvalued PS

82.89

Undervalued PS

9.28

Financials

Annual

Quarterly

FY2025Q1

YoY :

+15.14%

1.76M

Total Revenue

FY2025Q1

YoY :

-32.09%

-13.03M

Operating Profit

FY2025Q1

YoY :

+37.21%

-24.53M

Net Income after Tax

FY2025Q1

YoY :

+30.00%

-0.13

EPS - Diluted

FY2025Q1

YoY :

-30.94%

-13.39M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+19.16%

-1.39K

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

251.7K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

353.6K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

251.7K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABUS News & Events

Events Timeline

2025-06-25 (ET)

2025-06-25

07:32:32

Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB

2025-05-14 (ET)

2025-05-14

07:34:19

Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)

2025-05-07 (ET)

2025-05-07

05:31:46

Arbutus Biopharma presents data from two HBV assets

News

8.5

06-25Newsfilter

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

9.5

05-14SeekingAlpha

Arbutus Biopharma GAAP EPS of -$0.13 misses by $0.03, revenue of $1.76M beats by $0.17M

9.0

05-07Newsfilter

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025